Welcome to our dedicated page for OneMedNet SEC filings (Ticker: ONMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OneMedNet Corp. filings document the healthcare software company’s public-company disclosures, capital structure, and material events. The record includes 8-K reports on Regulation FD investor presentations, a private placement of common stock and pre-funded warrants, related voting and resale-registration arrangements, and continued-listing compliance matters for its Nasdaq-listed securities.
The filings identify OneMedNet’s common stock and redeemable warrants, including warrants exercisable for common shares, and provide formal disclosure around securities purchase agreements, governance-related voting provisions, exhibits, and market-listing notices. These documents frame the company’s financing activity and reporting obligations alongside its imaging real-world data business.
OneMedNet Corp director and 10% owner Thomas Kosasa bought additional common stock. On May 18, 2026, he acquired 268,817 shares of OneMedNet common stock at a reported price of $0.93 per share, increasing his direct holdings to 16,930,144 shares.
The purchase was made through a $250,000 investment in OneMedNet under a subscription agreement, with the shares valued at the volume-weighted average price for the 10 trading days immediately before the purchase date.
OneMedNet Corp director and 10% owner Thomas Kosasa bought additional common stock. On May 18, 2026, he acquired 268,817 shares of OneMedNet common stock at a reported price of $0.93 per share, increasing his direct holdings to 16,930,144 shares.
The purchase was made through a $250,000 investment in OneMedNet under a subscription agreement, with the shares valued at the volume-weighted average price for the 10 trading days immediately before the purchase date.
OneMedNet Corporation reported Q1 2026 revenue of $96,000 and a net loss of $2.5 million, reflecting a 30% revenue decline and wider losses versus Q1 2025. Cost of revenue of $0.5 million produced a negative gross margin, and operating expenses remained high at $2.2 million.
Cash and cash equivalents fell to $233,000 as of March 31, 2026, against $5.6 million of total liabilities and a stockholders’ deficit of $4.1 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern and is relying on equity financing, including a Yorkville SEPA draw and related-party subscriptions.
The company holds a small Bitcoin position, realizes gains and losses from sales, and received an April 2026 Nasdaq notice for noncompliance with the $1.00 minimum bid price rule, with a grace period to regain compliance.
OneMedNet Corporation reported Q1 2026 revenue of $96,000 and a net loss of $2.5 million, reflecting a 30% revenue decline and wider losses versus Q1 2025. Cost of revenue of $0.5 million produced a negative gross margin, and operating expenses remained high at $2.2 million.
Cash and cash equivalents fell to $233,000 as of March 31, 2026, against $5.6 million of total liabilities and a stockholders’ deficit of $4.1 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern and is relying on equity financing, including a Yorkville SEPA draw and related-party subscriptions.
The company holds a small Bitcoin position, realizes gains and losses from sales, and received an April 2026 Nasdaq notice for noncompliance with the $1.00 minimum bid price rule, with a grace period to regain compliance.
OneMedNet Corporation filed Amendment No. 1 to its annual report to add updated Part III information on directors, executive officers, compensation, ownership and related-party dealings. The company reports an aggregate market value of non‑affiliate common equity of $13.8 million as of June 30, 2025 and had 52,196,729 common shares outstanding as of March 27, 2026.
The filing details 2025 executive pay, including total compensation of $1,107,622 for CEO Aaron Green and $537,848 for founder and CMO Jeffrey Yu, largely driven by restricted stock unit grants. It outlines significant insider financings, such as conversion of about $3.3 million of shareholder and extension loans into 4,693,296 shares at $0.71 per share and earlier conversion of approximately $1.66 million of PIPE Notes into 1,453,174 shares at $1.14 per share. Additional private placements with directors in 2025–2026 provided several million dollars of cash proceeds at prices between $0.42 and $0.89 per share.
OneMedNet Corporation filed Amendment No. 1 to its annual report to add updated Part III information on directors, executive officers, compensation, ownership and related-party dealings. The company reports an aggregate market value of non‑affiliate common equity of $13.8 million as of June 30, 2025 and had 52,196,729 common shares outstanding as of March 27, 2026.
The filing details 2025 executive pay, including total compensation of $1,107,622 for CEO Aaron Green and $537,848 for founder and CMO Jeffrey Yu, largely driven by restricted stock unit grants. It outlines significant insider financings, such as conversion of about $3.3 million of shareholder and extension loans into 4,693,296 shares at $0.71 per share and earlier conversion of approximately $1.66 million of PIPE Notes into 1,453,174 shares at $1.14 per share. Additional private placements with directors in 2025–2026 provided several million dollars of cash proceeds at prices between $0.42 and $0.89 per share.
OneMedNet Corp director and Chief Medical Officer Jeffrey Yu increased his stake through a sizable cash investment and share grant. On April 1, 2026, he invested $750,000 in a subscription agreement, receiving 903,614 common shares at $0.83 each, and was issued 219,429 shares in lieu of prior cash compensation at the same price. Following these transactions, he directly owns 8,229,837 common shares. An additional 1,311,970 shares are held in a trust with an independent trustee, for which he disclaims beneficial ownership.
OneMedNet Corp director and Chief Medical Officer Jeffrey Yu increased his stake through a sizable cash investment and share grant. On April 1, 2026, he invested $750,000 in a subscription agreement, receiving 903,614 common shares at $0.83 each, and was issued 219,429 shares in lieu of prior cash compensation at the same price. Following these transactions, he directly owns 8,229,837 common shares. An additional 1,311,970 shares are held in a trust with an independent trustee, for which he disclaims beneficial ownership.
OneMedNet Corp director and ten percent owner Thomas Kosasa increased his direct holdings through two stock purchases. On February 6, 2026, he bought 595,238 shares of common stock at $0.84 per share under a $500,000 subscription agreement. On April 23, 2026, he purchased 280,898 shares at $0.89 per share under a $250,000 subscription agreement. These transactions total 876,136 shares and $750,000 of investment, bringing his direct ownership to 16,661,327 common shares after the latest purchase. The purchase prices were based on the volume-weighted average price over the 10 trading days before each purchase date.
OneMedNet Corp director and ten percent owner Thomas Kosasa increased his direct holdings through two stock purchases. On February 6, 2026, he bought 595,238 shares of common stock at $0.84 per share under a $500,000 subscription agreement. On April 23, 2026, he purchased 280,898 shares at $0.89 per share under a $250,000 subscription agreement. These transactions total 876,136 shares and $750,000 of investment, bringing his direct ownership to 16,661,327 common shares after the latest purchase. The purchase prices were based on the volume-weighted average price over the 10 trading days before each purchase date.
OneMedNet Corporation reported that Nasdaq has notified the company its common stock no longer meets the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days. The company has 180 days, until October 12, 2026, to regain compliance by having its share price at or above $1.00 for at least ten consecutive business days. If it still does not comply, OneMedNet may qualify for an additional 180-day period if it meets other Nasdaq Capital Market listing standards and commits to a plan that may include a reverse stock split. The company notes there is no assurance it will regain or maintain compliance, and failure to do so could result in Nasdaq delisting its shares.
OneMedNet Corporation reported that Nasdaq has notified the company its common stock no longer meets the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days. The company has 180 days, until October 12, 2026, to regain compliance by having its share price at or above $1.00 for at least ten consecutive business days. If it still does not comply, OneMedNet may qualify for an additional 180-day period if it meets other Nasdaq Capital Market listing standards and commits to a plan that may include a reverse stock split. The company notes there is no assurance it will regain or maintain compliance, and failure to do so could result in Nasdaq delisting its shares.
OneMedNet Corporation filed its annual report describing a niche business curating regulatory-grade imaging Real World Data for life sciences customers through a federated network of more than 2,130 healthcare sites. The company remains unprofitable, with net losses of $2.8 million in 2025 and $10.1 million in 2024 and an accumulated deficit of about $104.4 million, and its auditors raised substantial doubt about its ability to continue as a going concern. Management highlights a highly regulated, competitive environment, a workforce of roughly 23 employees, and heavy reliance on data privacy, cybersecurity and FDA-quality compliance. During 2025, OneMedNet completed equity financings, insider-led subscriptions and multiple debt-for-equity conversions that together eliminated roughly $11.9 million of current liabilities, which it states equals a 62% reduction in total liabilities outstanding as of year-end 2025, while also detailing extensive regulatory, operational and market risks.
OneMedNet Corporation filed its annual report describing a niche business curating regulatory-grade imaging Real World Data for life sciences customers through a federated network of more than 2,130 healthcare sites. The company remains unprofitable, with net losses of $2.8 million in 2025 and $10.1 million in 2024 and an accumulated deficit of about $104.4 million, and its auditors raised substantial doubt about its ability to continue as a going concern. Management highlights a highly regulated, competitive environment, a workforce of roughly 23 employees, and heavy reliance on data privacy, cybersecurity and FDA-quality compliance. During 2025, OneMedNet completed equity financings, insider-led subscriptions and multiple debt-for-equity conversions that together eliminated roughly $11.9 million of current liabilities, which it states equals a 62% reduction in total liabilities outstanding as of year-end 2025, while also detailing extensive regulatory, operational and market risks.
OneMedNet reported mixed results: operating revenue declined while non-operating items improved the bottom line. Total revenue was $155 thousand for the quarter (subscription $47k; web imaging $108k), down from $227k year-over-year, and gross margin was negative $(241)k. The company recorded net income of $2.98 million for the quarter and $1.08 million for the six months, driven largely by a $3.71 million gain on troubled debt restructurings, realized Bitcoin gains, and fair value adjustments.
Balance sheet and liquidity remain constrained: cash was $122k and Bitcoin fair value $1.598 million (15 units), total assets $2.337 million, and total liabilities fell to $6.177 million from $19.677 million due to debt-to-equity conversions and settlements. Stockholders' deficit improved to $(3.84) million. Management states the cash and Bitcoin balance are not adequate to fund operations for 12 months, raising substantial doubt about going concern and requiring additional financing.